These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 15922119)

  • 1. Potential therapeutic implication of nifedipine, a dihydropyridine-based calcium antagonist, in advanced glycation end product (AGE)-related disorders.
    Yamagishi S; Nakamura K; Takeuchi M
    Med Hypotheses; 2005; 65(2):392-4. PubMed ID: 15922119
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevention of diabetic vascular calcification by nifedipine, a dihydropyridine-based calcium channel blocker.
    Yamagishi S; Matsui T; Nakamura K
    Med Hypotheses; 2007; 68(5):1096-8. PubMed ID: 17097822
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel pleiotropic effect of atorvastatin on advanced glycation end product (AGE)-related disorders.
    Yamagishi S; Nakamura K; Matsui T; Inoue H
    Med Hypotheses; 2007; 69(2):338-40. PubMed ID: 17329034
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic potentials of unicellular green alga Chlorella in advanced glycation end product (AGE)-related disorders.
    Yamagishi S; Nakamura K; Inoue H
    Med Hypotheses; 2005; 65(5):953-5. PubMed ID: 15996828
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of advanced glycation end products (AGEs) and receptor for AGEs (RAGE) in vascular damage in diabetes.
    Yamagishi S
    Exp Gerontol; 2011 Apr; 46(4):217-24. PubMed ID: 21111800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nifedipine inhibits gene expression of receptor for advanced glycation end products (RAGE) in endothelial cells by suppressing reactive oxygen species generation.
    Yamagishi S; Takeuchi M
    Drugs Exp Clin Res; 2004; 30(4):169-75. PubMed ID: 15553663
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oral administration of AST-120 (Kremezin) is a promising therapeutic strategy for advanced glycation end product (AGE)-related disorders.
    Yamagishi S; Nakamura K; Matsui T; Inoue H; Takeuchi M
    Med Hypotheses; 2007; 69(3):666-8. PubMed ID: 17331665
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nifedipine, a calcium channel blocker, inhibits advanced glycation end product (AGE)-elicited mesangial cell damage by suppressing AGE receptor (RAGE) expression via peroxisome proliferator-activated receptor-gamma activation.
    Matsui T; Yamagishi S; Takeuchi M; Ueda S; Fukami K; Okuda S
    Biochem Biophys Res Commun; 2009 Jul; 385(2):269-72. PubMed ID: 19460355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nifedipine inhibits advanced glycation end products (AGEs) and their receptor (RAGE) interaction-mediated proximal tubular cell injury via peroxisome proliferator-activated receptor-gamma activation.
    Matsui T; Yamagishi S; Takeuchi M; Ueda S; Fukami K; Okuda S
    Biochem Biophys Res Commun; 2010 Jul; 398(2):326-30. PubMed ID: 20599709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Possible participation of advanced glycation end products in the pathogenesis of colorectal cancer in diabetic patients.
    Yamagishi S; Nakamura K; Inoue H; Kikuchi S; Takeuchi M
    Med Hypotheses; 2005; 64(6):1208-10. PubMed ID: 15823719
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential utility of statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors in diabetic retinopathy.
    Yamagishi S; Nakamura K; Matsui T; Sato T; Takeuchi M
    Med Hypotheses; 2006; 66(5):1019-21. PubMed ID: 16188392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advanced glycation end products and receptor-oxidative stress system in diabetic vascular complications.
    Yamagishi S
    Ther Apher Dial; 2009 Dec; 13(6):534-9. PubMed ID: 19954478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Possible participation of advanced glycation end products in the pathogenesis of osteoporosis in diabetic patients.
    Yamagishi S; Nakamura K; Inoue H
    Med Hypotheses; 2005; 65(6):1013-5. PubMed ID: 16146671
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blockade by nifedipine of advanced glycation end product-induced CD40-CD40 ligand interaction in endothelial cells.
    Yamagishi S; Kikuchi S; Takenaka K; Takeuchi M
    Drugs Exp Clin Res; 2005; 31(5-6):221-6. PubMed ID: 16425979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum or cerebrospinal fluid levels of glyceraldehyde-derived advanced glycation end products (AGEs) may be a promising biomarker for early detection of Alzheimer's disease.
    Yamagishi S; Nakamura K; Inoue H; Kikuchi S; Takeuchi M
    Med Hypotheses; 2005; 64(6):1205-7. PubMed ID: 15823718
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nifedipine, a calcium channel blocker, inhibits inflammatory and fibrogenic gene expressions in advanced glycation end product (AGE)-exposed fibroblasts via mineralocorticoid receptor antagonistic activity.
    Matsui T; Takeuchi M; Yamagishi S
    Biochem Biophys Res Commun; 2010 May; 396(2):566-70. PubMed ID: 20438710
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A possible involvement of crosstalk between advanced glycation end products (AGEs) and asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase inhibitor in accelerated atherosclerosis in diabetes.
    Yamagishi S; Ueda S; Okuda S
    Med Hypotheses; 2007; 69(4):922-4. PubMed ID: 17368960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Minodronate, a nitrogen-containing bisphosphonate, inhibits advanced glycation end product-induced vascular cell adhesion molecule-1 expression in endothelial cells by suppressing reactive oxygen species generation.
    Yamagishi S; Matsui T; Nakamura K; Takeuchi M
    Int J Tissue React; 2005; 27(4):189-95. PubMed ID: 16440584
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atheroprotective properties of nifedipine.
    Yamagishi S; Takeuchi M
    Int J Tissue React; 2005; 27(2):63-7. PubMed ID: 16035650
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Revival of nifedipine, a dihydropyridine-based calcium blocker.
    Yamagishi S; Nakamura K
    Med Hypotheses; 2007; 68(3):565-7. PubMed ID: 17011717
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.